Cargando…

Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries

OBJECTIVE: To identify pharmaceutical policy changes during the economic recession in eight European countries and to determine whether policy measures resulted in lower sales of, and less expenditure on, pharmaceuticals. METHODS: Information on pharmaceutical policy changes between 2008 and 2011 in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leopold, Christine, Mantel-Teeuwisse, Aukje K, Vogler, Sabine, Valkova, Silvia, de Joncheere, Kees, Leufkens, Hubert GM, Wagner, Anita K, Ross-Degnan, Dennis, Laing, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Health Organization 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208566/ https://www.ncbi.nlm.nih.gov/pubmed/25378754 http://dx.doi.org/10.2471/BLT.13.129114

Ejemplares similares

Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses
por: Leopold, Christine, et al.
Publicado: (2014)

Impact of External Price Referencing on Medicine Prices – A Price Comparison Among 14 European Countries
por: Leopold, Christine, et al.
Publicado: (2012)

Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference
por: Vogler, Sabine, et al.
Publicado: (2016)

National medicines policies – a review of the evolution and development processes
por: Hoebert, Joëlle M, et al.
Publicado: (2013)

Pharmaceutical policies in European countries in response to the global financial crisis
por: Vogler, Sabine, et al.
Publicado: (2011)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research?
por: Vogler, Sabine, et al.
Publicado: (2015)

Adverse events and patients’ perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia
por: Sagwa, Evans L, et al.
Publicado: (2016)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Systematic reviews of ten pharmaceutical pricing policies – a research protocol
por: Tordrup, David, et al.
Publicado: (2020)

Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study
por: Ankrah, Daniel N. A., et al.
Publicado: (2017)

Essential Medicines Are More Available than Other Medicines around the Globe
por: Bazargani, Yaser T., et al.
Publicado: (2014)

Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019
por: Kusynová, Zuzana, et al.
Publicado: (2022)

Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa
por: Narsai, Kirti, et al.
Publicado: (2012)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013)

Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
por: Willemen, Marjolein J., et al.
Publicado: (2011)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2013)

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort
por: Sagwa, Evans L., et al.
Publicado: (2015)

Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: a cross-sectional assessment of availability, prices and affordability
por: Kibira, Denis, et al.
Publicado: (2021)

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
por: Vreman, Rick A., et al.
Publicado: (2020)

Medicine shortages: impact behind numbers
por: Postma, Doerine J., et al.
Publicado: (2023)

Impact of medicine shortages on patients - a framework and application in the Netherlands
por: Postma, Doerine J., et al.
Publicado: (2022)

Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review
por: Jacobs, Tom G., et al.
Publicado: (2019)

Post‐marketing dosing changes in the label of biologicals
por: Minnema, Lotte A., et al.
Publicado: (2019)

Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia
por: Kibira, Denis, et al.
Publicado: (2021)

The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals
por: Ebbers, Hans C., et al.
Publicado: (2012)

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
por: Vreman, Rick A., et al.
Publicado: (2020)

Essential medicines for breast cancer in low and middle income countries
por: Bazargani, Y. T., et al.
Publicado: (2015)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana
por: Tetteh, Raymond A., et al.
Publicado: (2015)

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
por: Tetteh, Raymond A., et al.
Publicado: (2016)

Drug Shortages From the Perspectives of Authorities and Pharmacy Practice in the Netherlands: An Observational Study
por: Postma, Doerine J., et al.
Publicado: (2018)

Tenofovir-associated renal toxicity in a cohort of HIV infected patients in Ghana
por: Nartey, Edmund T., et al.
Publicado: (2019)

Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018
por: Kibira, Denis, et al.
Publicado: (2021)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Linking market authorizations of medicines with disease burden in South Africa
por: Narsai, K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nm8hui41m4m3guvvcefca3fmgh